Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin Market Outlook For 2008

This article was originally published in PharmAsia News

Executive Summary

In 2007, vitamin products-calcium pantothenate, folic acid, vitamins A, B2, and C-experienced high price increase. Analysts attribute the hike to the monopoly enjoyed by major companies, as well as the inflated cost of raw materials. However, observers do not expect vitamin products to continue enjoying such strong growth in 2008; the temporary price spike was caused by increased costs in infrastructure, environmental management, raw materials and labor. Mostly, vitamin prices hover around cost, and more competitors entering the market will add to the depression. Last year's adjustment of export tax rebates have adversely impacted many sectors; the clamp-down on high-energy, high-polluting industries will further curtail the development of many companies, including those producing vitamins. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel